Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Enliven Therapeutics, Inc. (ELVN) had Consolidated Net Income/Loss of $-89.02M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-89.02M |
|
-- |
|
-- |
|
$104.55M |
|
$-104.55M |
|
$15.53M |
|
$-89.02M |
|
$-89.02M |
|
$-89.02M |
|
$-89.02M |
|
|
Consolidated Net Income/Loss |
$-89.02M |
$-89.02M |
|
$-104.55M |
|
$-103.81M |
|
47.07M |
|
47.07M |
|
$-1.89 |
|
$-1.89 |
|
| Balance Sheet Financials | |
$318.13M |
|
$0.46M |
|
$7.63M |
|
$325.76M |
|
$15.91M |
|
-- |
|
-- |
|
$15.91M |
|
$309.85M |
|
$309.85M |
|
$309.85M |
|
48.94M |
|
| Cash Flow Statement Financials | |
$-73.19M |
|
$-36.00M |
|
$133.16M |
|
$100.19M |
|
$124.17M |
|
$23.98M |
|
$20.17M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.99 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-73.24M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-28.73% |
|
-28.73% |
|
-27.33% |
|
-28.73% |
|
$6.33 |
|
$-1.56 |
|
$-1.55 |
|